Safaei H, Janghorbani M, Aminorroaya A, Amini M
Department of Epidemiology and Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Acta Diabetol. 2007 Jun;44(2):76-82. doi: 10.1007/s00592-007-0246-6. Epub 2007 May 27.
The objective of this study was to examine the effects of lovastatin on bone mineral density (BMD) of postmenopausal women with type 2 diabetes mellitus (DM). The study was an open-label clinical trial conducted from March 2002 to November 2003. Fifty-five postmenopausal women age 54-67 years with type 2 DM were allocated to lovastatin-treated and control (without lovastatin) groups based on low-density lipoprotein cholesterol (LDL-C) >130 or < or =130 mg/dl. The first group received lovastatin (20 mg daily titrated every 3 months to keep LDL-C less than 130 mg/dl) for a total of 18 months. The second group received their own diabetic regimen without statin. The BMD of the lumbar spine (L1 - L4), femoral neck, Wards triangle, trochanter and total hip was measured by dual-energy X-ray absorptiometry at baseline and after 18 months. In the 28 women treated with lovastatin, the BMD increased in lumbar spine (from 0.946 (0.122) to 0.978 (0.135) g/cm2, p<0.01) and Ward's triangle (from 0.685 (0.123) to 0.780 (0.186) g/cm2, p<0.01). In the 27 women not treated with statin, the changes in BMD at all bone sites were not statistically significant. BMD was higher in femoral neck (1.2% vs. -2.7%, p<0.05), Ward's triangle (13.9% vs. 3.3%, p<0.05), trochanter (-0.1% vs. -2.9%, p<0.05), total hip (1.2% vs. -1.4%, p<0.05) and lumbar spine (3.4% vs. 1.2%, p>0.05) at the end of the study. Treatment with lovastatin may prevent bone loss in postmenopausal women with type 2 DM.
本研究的目的是检测洛伐他汀对绝经后2型糖尿病（DM）女性骨密度（BMD）的影响。该研究是一项开放标签的临床试验，于2002年3月至2003年11月进行。55名年龄在54 - 67岁的绝经后2型糖尿病女性根据低密度脂蛋白胆固醇（LDL-C）>130或≤130 mg/dl被分配到洛伐他汀治疗组和对照组（未使用洛伐他汀）。第一组接受洛伐他汀（每日20 mg，每3个月滴定一次以保持LDL-C低于130 mg/dl），共18个月。第二组接受其自身的糖尿病治疗方案，不使用他汀类药物。在基线和18个月后，通过双能X线吸收法测量腰椎（L1 - L4）、股骨颈、Ward三角、大转子和全髋的骨密度。在28名接受洛伐他汀治疗的女性中，腰椎骨密度增加（从0.946（0.122）增加到0.978（0.135）g/cm²，p<0.01），Ward三角骨密度增加（从0.685（0.123）增加到0.780（0.186）g/cm²，p<0.01）。在27名未接受他汀类药物治疗的女性中，所有骨部位的骨密度变化无统计学意义。在研究结束时，股骨颈（1.2%对 - 2.7%，p<0.05）、Ward三角（13.9%对3.3%，p<0.05）、大转子（ - 0.1%对 - 2.9%，p<0.05）、全髋（1.2%对 - 1.4%，p<0.05）和腰椎（3.4%对1.2%，p>0.05）的骨密度更高。洛伐他汀治疗可能预防绝经后2型糖尿病女性的骨质流失。
